CanSino Biologics Inc. (HKG:6185)

CanSino Biologics Revenue

CanSino Biologics had revenue of 359.54M CNY in the quarter ending June 30, 2026, with 46.65% growth. This brings the company's total for the last twelve months to 1.24B, up 33.52% year-over-year. In the year 2025, CanSino Biologics had annual revenue of 1.07B with 26.18% growth. That makes CanSino Biologics the 18,156th largest company in the world by revenue and 1,057th in Hong Kong.

• Revenue (ttm): 1.24B CNY
• Revenue Growth: +33.52%
• P/S Ratio: 10.31
• Revenue / Employee: 1.05M CNY
• Employees: 1,175
• Market Cap: 14.14B HKD

Revenue Chart

Chart

Chart

* This company reports financials in CNY.

Revenue by Geography

Chart

• People's Republic of China (PRC) 1.01B 95.5%
• Overseas 47.75M 4.5%

Fiscal year ended Dec 31, 2025 See the full CanSino Biologics breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	1.07B	221.57M	26.18%
Dec 31, 2024	846.34M	489.25M	137.01%
Dec 31, 2023	357.08M	-677.51M	-65.49%
Dec 31, 2022	1.03B	-3.27B	-75.94%
Dec 31, 2021	4.30B	4.27B	17,174.82%

Data Source: S&P Global Market Intelligence Last updated: Aug 27, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 17, 2026

Data Sources Report a data error